These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 11145251)

  • 21. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.
    Granter SR; Weilbaecher KN; Quigley C; Fisher DE
    Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):47-51. PubMed ID: 11893035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi.
    Shah IA; Gani OS; Wheler L
    Pathol Res Pract; 1997; 193(7):497-502. PubMed ID: 9342756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas.
    Vachtenheim J; Novotná H
    Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):1075-82. PubMed ID: 10644012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous desmoplastic melanoma.
    Busam KJ
    Adv Anat Pathol; 2005 Mar; 12(2):92-102. PubMed ID: 15731577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
    Keller-Melchior R; Schmidt R; Piepkorn M
    J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
    Shanesmith RP; Smart C; Cassarino DS
    Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nevi, other than dysplastic and Spitz nevi.
    Cochran AJ; Bailly C; Paul E; Dolbeau D
    Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fascin expression in melanocytic lesions of the skin.
    YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
    Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations.
    Nybakken GE; Sargen M; Abraham R; Zhang PJ; Ming M; Xu X
    Am J Dermatopathol; 2013 Feb; 35(1):25-9. PubMed ID: 22668579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
    Rao Q; Wang Y; Xia QY; Shi SS; Shen Q; Tu P; Shi QL; Zhou XJ; Wu B
    Int J Clin Exp Pathol; 2014; 7(3):1132-9. PubMed ID: 24696729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
    Nazarian RM; Prieto VG; Elder DE; Duncan LM
    J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
    Clarkson KS; Sturdgess IC; Molyneux AJ
    J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
    Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
    Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical studies of conjunctival nevi and melanomas.
    Jakobiec FA; Bhat P; Colby KA
    Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
    Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
    J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microphthalmia transcription factor: a specific marker for malignant melanoma.
    Vachtenheim J; Borovanský J
    Prague Med Rep; 2004; 105(3):318-24. PubMed ID: 15782558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).
    Medic S; Ziman M
    PLoS One; 2010 Apr; 5(4):e9977. PubMed ID: 20421967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
    Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
    Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.